title: Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011.
abstract: Antibody cross-reactivity to the influenza A(H3N2) variant virus recently reported in the United States, was investigated in Norwegian sera. Seroprevalence was 40% overall, and 71% in people born between 1977 and 1993. The most susceptible age groups were children and people aged around 50 years. The high immunity in young adults is likely to be due to strong priming infection with similar viruses in the 1990s. More research is needed to explain the poor immunity in 45–54 year-olds.
authors.affiliation: Department of Virology, Norwegian Institute of Public Health, Oslo, Norway. kristian.waalen@fhi.no
authors.forename: K
authors.initials: K
authors.lastname: Waalen
authors.forename: A
authors.initials: A
authors.lastname: Kilander
authors.forename: S G
authors.initials: SG
authors.lastname: Dudman
authors.forename: R
authors.initials: R
authors.lastname: Ramos-Ocao
authors.forename: O
authors.initials: O
authors.lastname: Hungnes
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D002675:Child, Preschool; D003429:Cross Reactions / Q000276:immunology; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology* / Q000302:isolation & purification; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D015995:Prevalence; D016036:Seroepidemiologic Studies; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines